Ethical considerations in post-market-approval monitoring and regulation of vaccines regulation of vaccines : Vaccination EthicsTHOMPSON, Alison; KOMPARIC, Ana; SMITH, Maxwell J et al.Vaccine. 2014, Vol 32, Num 52, pp 7171-7174, issn 0264-410X, 4 p.Article

Pharmacovigilance = Pharmacovigilance updateLIVIO, F; BIOLLAZ, J; BUCLIN, T et al.Revue médicale suisse. 2011, Vol 7, Num 277, pp 71-74, issn 1660-9379, 4 p.Article

Pharmacovigilance et tératovigilance = Pharmacovigilance and teratovigilanceLIVIO, F; BUCLIN, T; BIOLLAZ, J et al.Revue médicale suisse. 2007, Vol 3, Num 95, pp 238-242, issn 1660-9379, 5 p.Article

Pharmacovigilance : NOUVEAUTES EN MEDECINE 2011 (DEUXIEME PARTIE) = PharmacovigilanceLIVIO, F; RENARD, D; BUCLIN, T et al.Revue médicale suisse. 2012, Vol 8, Num 324, pp 116-119, issn 1660-9379, 4 p.Article

PharmacovigilanceIMBS, Jean-Louis.La Revue du praticien. Médecine générale. 2007, Num 790, pp 1139-1144, issn 0989-2737, 6 p.Article

The challenge of biosimilarsMELLSTEDT, H; NIEDERWIESER, D; LUDWIG, H et al.Annals of oncology. 2008, Vol 19, Num 3, pp 411-419, issn 0923-7534, 9 p.Article

Strategies for Developing Pharmacovigilance. ISoP Annual MeetingDrug safety. 2008, Vol 31, Num 10, pp 885-960, issn 0114-5916, 75 p.Conference Paper

The Renaissance of PharmacovigilanceDrug safety. 2013, Vol 36, Num 9, pp 793-951, issn 0114-5916, 159 p.Conference Paper

MEDIATOR : un médicament au coeur de l'actualitéWILT, Catherine.2012, 139 p.Thesis

The future of pharmacovigilance : a personal viewEDWARDS, I. Ralph.European journal of clinical pharmacology. 2008, Vol 64, Num 2, pp 173-181, issn 0031-6970, 9 p.Article

The importance of direct patient reporting of suspected adverse drug reactions: a patient perspectiveANDERSON, Claire; KRSKA, Janet; MURPHY, Elizabeth et al.British journal of clinical pharmacology. 2011, Vol 72, Num 5, pp 806-822, issn 0306-5251, 17 p.Article

Off-Label PharmacovigilanceRALPH EDWARDS, I.Drug safety. 2011, Vol 34, Num 10, pp 795-797, issn 0114-5916, 3 p.Article

Pharmacovigilance : Nouveautés en médecine 2007 (Deuxième partie) = Pharmacovigilance UpdateLIVIO, F; BUCLIN, T; BIOLLAZ, J et al.Revue médicale suisse. 2008, Vol 4, Num 140, pp 150-154, issn 1660-9379, 5 p.Article

Congrès annuel de la Société Française de PharmacologieThérapie (Paris). 1998, Vol 53, Num 2, pp 169-196, issn 0040-5957Conference Proceedings

Le point sur la pharmacovigilanceCAHIERS HOSPITALIERS. 1995, Num 108, pp 9-10, issn 0295-4591Article

ISoP Annual MeetingDrug safety. 2007, Vol 30, Num 10, pp 919-990, issn 0114-5916, 71 p.Conference Paper

La pharmacovigilance = PharmacovigilanceCARLHANT-KOWALKI, D; BROCH, C.Médecine & enfance. 2001, Vol 21, Num 8, pp 389-391, issn 0291-0233, 1Article

Le point sur les produits antihémophiliquesLOPEZ, Isabelle; WALLET, Patrick.Le Pharmacien hospitalier. 1996, Num 127, issn 0768-9179, non paginé [8 p.], SupplSerial Issue

Results from the First Decade of Research Conducted by the Research on Adverse Drug Events and Reports (RADAR) ProjectMCKOY, June M; FISHER, Matthew J; NARDONE, Beatrice et al.Drug safety. 2013, Vol 36, Num 5, pp 335-347, issn 0114-5916, 13 p.Article

Pharmacovigilance Update : Nouveautés en médecine 2009: deuxième partie = Pharmacovigilance UpdateLIVIO, F; BIOLLAZ, J; ROTHUIZEN, L et al.Revue médicale suisse. 2010, Vol 6, Num 232, pp 128-131, issn 1660-9379, 4 p.Article

Vingt-troisièmes journées françaises de pharmacovigilance : Les faits marquants = The Twenty-third French Congress of Pharmacovigilance : what's newLa Revue Prescrire. 2002, Vol 22, Num 232, pp 670-675, issn 0247-7750, 6 p.Article

Pharmaco... vigilance !BEGAUD, B.La Lettre du pharmacologue (Boulogne). 2002, Vol 16, Num 3, pp 70-71, issn 0984-452XConference Paper

Suivi de pharmacovigilance du vaccin Prevenar® = Post licensure safety surveillance for Prevenar®BENSOUDA-GRIMALDI, L; JONVILLE-BERA, A.-P; AUTRET-LECA, E et al.Archives de pédiatrie (Paris). 2007, Vol 14, Num 7, pp 870-874, issn 0929-693X, 5 p.Article

Anomalies hématologiques du natalizumab et sa signification clinique = Hematological side effects of natalizumab: Correlation with clinical outcomeBRESCH, S; COHEN, M; ROCHER, F et al.Revue neurologique (Paris). 2012, Vol 168, Num 2, pp 116-120, issn 0035-3787, 5 p.Article

Improving global monitoring of vaccine safety: e* : A quantitative analysis of adverse event reports in the WHO Adverse Reactions DatabaseLETOURNEAU, Megan; WELLS, George; WALOP, Wikke et al.Vaccine. 2008, Vol 26, Num 9, pp 1185-1194, issn 0264-410X, 10 p.Article